Medigen Biotechnology Corporation
11
2
2
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
9.1%
1 terminated/withdrawn out of 11 trials
87.5%
+1.0% vs industry average
9%
1 trials in Phase 3/4
43%
3 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Phase I/II Study: Allogeneic NK-cell Therapy With Chemotherapy for Post-Surgery PDA or Cholangiocarcinoma Patients
Role: lead
A Phase I, Autologous ex Vivo Expanded and Activated NK Cell, Magicell-NK, Infusion for Colon Cancer Post Resection Study
Role: lead
Study of PI-88 in Patients With Advanced Melanoma
Role: collaborator
Docetaxel With or Without PI-88 in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Role: collaborator
Trial of PI-88 With Docetaxel in Advanced Non-Small-Cell Lung Cancer (NSCLC)
Role: collaborator
PI-88 in Treating Patients With an Advanced Malignancy (Cancer) or Stage IV Melanoma
Role: collaborator
PI-88 in Hepatocellular Carcinoma After Hepatectomy
Role: collaborator
A Phase III PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related HCC After Surgical Resection
Role: collaborator
Trial of PI-88 With Dacarbazine in Patients With Metastatic Melanoma
Role: collaborator
Phase I Study to Evaluate the Safety and Efficacy of Telomelysin (OBP-301) in Patients With Hepatocellular Carcinoma
Role: collaborator
A Phase I Study to Evaluate the Safety, Reactogenicity, and Humoral Immune Responses to an Inactivated H5N1 Influenza Vaccine
Role: lead
All 11 trials loaded